Business Overview:^[1][2]
a) CBPL, under the brand name CBC, is engaged in manufacturing pharmaceutical formulations such as intravenous (IV) and intramuscular (IM) injections, tablets, and capsules
for both domestic and international markets.
b) The company operates primarily through contract manufacturing and job work arrangements, while maintaining
a diversified product portfolio across a multiple therapeutic segments including oncology, antibiotics, anesthesia, hormones, orthopedics, cardiology, nephrology, neurology, pediatrics, antifungal, and antiviral treatments.
c) In addition to formulations, CBPL is actively involved in the ethical promotion and marketing of Active Pharmaceutical Ingredients (APIs), specialty chemicals, and intermediates, leveraging its own distribution network and sales force.
d) Its major focus lies in supplying critical disease treatments—particularly injections, tablets, and capsules—to hospitals, healthcare centers, government institutions, NGOs, and distributors, combining sourcing, marketing, supply of both generic and branded medicines with a presence in domestic and international markets.